Oxcia contracts Patheon for manufacturing and further strengthens the organization
Oxcia, a pioneer in oxidative DNA damage and DNA Damage Response (DDR) with a focus on developing new safe treatments for cancer and inflammation, has contracted Patheon for upscaling and production of OXC-101 substance and tablets for the upcoming Phase 2 clinical trials. OXC-101 is Oxcia's first-in-class anticancer drug candidate, currently in phase 1 studies in patients with advanced solid cancers or blood cancers.
Patheon is part of the global ThermoFisher Scientific Group and is a leading contract manufacturer with production in several countries.
Oxcia continues to strengthen the organization. We are happy that Emil Lindmark has agreed to join us as a business lawyer. He comes most recently from a position as administrative lawyer at the Environment and Urban Planning Office in Lidingö municipality, where he was also part of the management team. Emil Lindmark received his law education at Umeå University. He has a law degree and a master's degree in land and environmental law. Emil will start his service at Oxcia in March 2022.
“Oxcia's project development is in an intensive phase and it feels reassuring that we have such a competent and efficient team with broad collective experience that drives it forward. As OXC-101 moves towards key clinical milestones, important collaborations are also established to ensure that development continues according to our carefully defined plan” says Ulrika Warpman Berglund, CEO of Oxcia.
For further information please contact:
Ulrika Warpman Berglund, CEO
Phone: +46 (0) 73 270 96 05
Email: ulrika.warpmanberglund@oxcia.com
Briefly about Oxcia
Oxcia AB is a pioneer in oxidative DNA damage and DNA Damage Response (DDR) with a focus on developing new safe treatments for patients suffering from diseases caused by cancer or inflammation. Oxcia currently has two DDR drug candidates, both with the potential to become first-in-class drugs. OXC-101 (Karonudib, TH1579) is being investigated in two ongoing clinical phase 1 studies, one in advanced solid tumors and one in hematological cancers. OXC-201 (TH5487) is developed against inflammatory and fibrosis-related diseases, such as pulmonary fibrosis, and is in the preclinical phase.
More information about Oxcia is available at www.oxcia.com